Compare HGBL & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HGBL | NTRB |
|---|---|---|
| Founded | 1937 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.6M | 36.0M |
| IPO Year | 1998 | 2019 |
| Metric | HGBL | NTRB |
|---|---|---|
| Price | $1.36 | $5.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.85 | N/A |
| AVG Volume (30 Days) | ★ 332.8K | 32.5K |
| Earning Date | 05-07-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,129,000.00 | $2,036,651.00 |
| Revenue This Year | $11.92 | $30.17 |
| Revenue Next Year | $13.52 | $3,394.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.01 | $2.80 |
| 52 Week High | $1.93 | $8.63 |
| Indicator | HGBL | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 63.90 | 77.22 |
| Support Level | $1.18 | $4.23 |
| Resistance Level | $1.42 | $6.41 |
| Average True Range (ATR) | 0.07 | 0.47 |
| MACD | 0.03 | 0.11 |
| Stochastic Oscillator | 85.74 | 90.03 |
Heritage Global Inc values and monetizes industrial and financial assets by providing acquisition, disposition, valuation, and lending services for surplus and distressed assets. It operates in four segments. The Auction and Liquidation segment, which operates as a full-service auction, appraisal, and asset advisory firm, includes the acquisition of turnkey manufacturing facilities and used industrial machinery and equipment. The Refurbishment & Resale segment acquires, refurbishes, and supplies specialized laboratory equipment. Brokerage segment, through NLEX, brokers charged-off receivables in the U.S. and Canada on behalf of financial institutions. The Specialty Lending segment, which provides specialty financing solutions to investors in charged-off and nonperforming asset portfolios.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.